vildagliptin/metformin sanoswiss 50 mg/850 mg apvalkotās tabletes
sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
vildagliptin/metformin sanoswiss 50 mg/1000 mg apvalkotās tabletes
sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
asigefort 50 mg/850 mg apvalkotās tabletes
tad pharma gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
asigefort 50 mg/1000 mg apvalkotās tabletes
tad pharma gmbh, germany - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
jivolar 50 mg/850 mg apvalkotās tabletes
medochemie ltd., cyprus - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
jivolar 50 mg/1000 mg apvalkotās tabletes
medochemie ltd., cyprus - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
sitagliptin/metformin billev 50 mg/850 mg apvalkotās tabletes
billev farmacija vzhod d.o.o., slovenia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg
sitagliptin/metformin billev 50 mg/1000 mg apvalkotās tabletes
billev farmacija vzhod d.o.o., slovenia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiski līdzekļi - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.